Compounds > reveromycin b
Page last updated: 2024-11-12

reveromycin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

reveromycin B: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10865248
CHEMBL ID115216
MeSH IDM0364238

Synonyms (8)

Synonym
CHEMBL115216
reveromycin b
bdbm50217842
144860-68-4
J-008016
Q57499770
(2e,4s,5s,6e,8e)-10-[(2r,5s,8s,9r)-2-butyl-2-[(1s,2e,4e)-5-carboxy-1-(3-carboxypropanoyloxy)-4-methylpenta-2,4-dienyl]-8-methyl-1,10-dioxaspiro[4.5]decan-9-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
AKOS040756196
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID91635Inhibitory concentration against Isoleucyl-tRNA synthetase (IleRS) activity2002Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23
Chemical modification of reveromycin A and its biological activities.
AID227685In vitro inhibition of protein synthesis in srcts-NRK cell at 1 ug/mL2002Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23
Chemical modification of reveromycin A and its biological activities.
AID406785Induction of apoptosis in mouse osteoclasts2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Synthesis and biological activities of reveromycin A and spirofungin A derivatives.
AID406779Effect on morphological reversion in src transformed NRK cells at 100 ug/mL2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Synthesis and biological activities of reveromycin A and spirofungin A derivatives.
AID406782Effect on morphological reversion in src transformed NRK cells at 3 ug/mL2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Synthesis and biological activities of reveromycin A and spirofungin A derivatives.
AID406778Inhibition of IleRS2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Synthesis and biological activities of reveromycin A and spirofungin A derivatives.
AID227691Morphological reversion of srcts-NRK cells concentration at 100 ug/mL2002Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23
Chemical modification of reveromycin A and its biological activities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's6 (85.71)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
reveromycin a
reveromycin A: from an actinomycete strain; structure given in first source; inhibits the mitogenic activity of the epidermal growth factor		2.0210
spirofungin b
spirofungin B: isolated from Streptomyces; structure in first source		2.0410
spirofungin a
spirofungin A: isolated from Streptomyces violaceusniger; structure in first source		2.0410
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		7.4120
ConditionIndicatedRelationship StrengthStudiesTrials